A Randomized Phase II Study Comparing Sequential High Dose Testosterone and Enzalutamide to Enzalutamide Alone in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Enzalutamide (Primary) ; Testosterone cipionate (Primary) ; Testosterone enanthate (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

03 Feb 2021 Protocol amended to add arm C (Variable Sequential Testosterone and Enzalutamide) in the trial, planned number of patients changed as reported by clinicaltrial.gov record.
03 Feb 2021 Planned number of patients changed from 90 to 150.
03 Feb 2021 Status changed from active, no longer recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com